Reddy's launches biosimilar rituximab

Dr. %27 (RDY) launched Reditux rituximab to treat non-Hodgkin's lymphoma (NHL) in India. RDY said the MAb will be available at a price of about Rs. 10,000 ($245) per 500 mg vial, or about half the pri...